A Phase I Trial of Simmitinib in Advanced Solid Tumors
This is an open label, multi-center, phase I study of oral Simmitinib in subjects with advanced solid tumors including gastric cancer.
Advanced Solid Tumor
DRUG: Simmitinib
Dose-limited toxicity (DLT), To identify the dose-limited toxicity (DLT)., 1 year|Maximum tolerated dose (MTD), To identify the maximum tolerated dose (MTD)., 1 year|Recommended Phase II Dose (RP2D), To identify the Recommended Phase II Dose (RP2D)., 1 year
Area under the plasma concentration versus time curve (AUC), To preliminarily evaluate the AUC in patients with advanced solid tumors., 2 year|Peak Plasma Concentration (Cmax), To preliminarily evaluate Cmax in patients with advanced solid tumors., 2 year|Time of peak plasma concentration (Tmax), To preliminarily evaluate Tmax in patients with advanced solid tumors., 2 year|Overall response rate (ORR), To preliminarily evaluate ORR in patients with advanced solid tumors., 2 year|Duration of Response (DoR), To preliminarily evaluate DoR in patients with advanced solid tumors., 2 year|Median progression free survival (PFS), To preliminarily evaluate PFS in patients with advanced solid tumors., 2 year|Median overall survival (OS), To preliminarily evaluate OS in patients with advanced solid tumors., 2 year|Gene status, FGFR1-4, VEGFA, CSF1, CSF1R and other related gene status, 2 year
This is an open label, multi-center, phase I study of oral Simmitinib in subjects with advanced solid tumors including gastric cancer \[including gastroesophageal cancer\], cholangiocarcinoma, lung squamous cell carcinoma, urothelial transitional cell carcinoma, and estrogen-receptor-positive breast cancer patients \[ER+\], etc. This phase I study will evaluate the safety, tolerability, pharmacokinetics and the preliminary efficacy of the FGFR/KDR/CSF1R multi-target inhibitor Simmitinib.